Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | ALPL | P05186 | 1/20 | 0.59 |
| ▸ | ALPI | P09923 | 1/20 | 0.59 |
| ▸ | ALPG | P10696 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.55 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10949439 | 0.86 | USP2 (0.63) | KMT2AHPGDRAB9ASMN1; SMN2GAA | |
| SCHEMBL11775788 | 0.83 | KMT2A (0.69) | KMT2AHPGDRAB9ASMN1; SMN2GAA | |
| SCHEMBL7821754 | 0.81 | ALOX15 (0.68) | KMT2AHPGDRAB9ASMN1; SMN2GAA | |
| SCHEMBL8184182 | 0.81 | RECQL (0.70) | KMT2AHPGDRAB9ASMN1; SMN2GAA | |
| SCHEMBL1433698 | 0.81 | RAB9A (0.81) | KMT2AHPGDRAB9ASMN1; SMN2HTT | |
| SCHEMBL3623600 | 0.81 | KMT2A (0.62) | KMT2AHPGDRAB9ASMN1; SMN2GAA | |
| SCHEMBL11301701 | 0.81 | SMN1; SMN2 (0.88) | KMT2AHPGDRAB9ASMN1; SMN2GAA | |
| SCHEMBL10903296 | 0.80 | KMT2A (0.67) | KMT2AHPGDRAB9AGAAHTT | |
| SCHEMBL5272168 | 0.80 | KMT2A (1.00) | KMT2AHPGDRAB9ASMN1; SMN2HTT | |
| SCHEMBL10948513 | 0.79 | KMT2A (0.63) | KMT2AHPGDRAB9ASMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1673349-B1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S BIO PTE LTD (SG) | 2010-06-30 | — | — | EP | claimed |
| EP-1673349-A4 | BENZIMIDAZOLE DERIVATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S BIO PTE LTD (SG) | 2008-01-23 | — | — | EP | claimed |
| JP-2007505942-A | — | — | 2007-03-15 | — | — | JP | claimed |
| US-20070043043-A1 | Benzimidazole derivates: preparation and pharmaceutical applications | S*BIO PTE LTD. (SG) | 2007-02-22 | — | — | US | claimed |
| EP-1673349-A1 | BENZIMIDAZOLE DERIVATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*Bio Pte Ltd (SG) | 2006-06-28 | — | — | EP | claimed |
| WO-2005028447-A1 | BENZIMIDAZOLE DERIVATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD (SG) | 2005-03-31 | — | — | WO | claimed |
| US-10736881-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | MEI PHARMA, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190282547-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD. (SG) | 2019-09-19 | — | — | US | disclosed |
| US-10201527-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | MEI PHARMA, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170360757-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD. (SG) | 2017-12-21 | — | — | US | disclosed |
| US-9717713-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | MEI PHARMA, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20160279102-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD. (SG) | 2016-09-29 | — | — | US | disclosed |
| US-9402829-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | MEI PHARMA, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| WO-2006101456-A1 | BICYCLIC HETEROCYCLES HYDROXAMATE COMPOUNDS USEFUL AS HISTONE DEACETYLASE (HDAC) INHIBITORS | S*BIO PTE LTD (SG) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006101455-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD (SG) | 2006-09-28 | — | — | WO | disclosed |
| EP-1673349-A1 | BENZIMIDAZOLE DERIVATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*Bio Pte Ltd (SG) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005028447-A1 | BENZIMIDAZOLE DERIVATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD (SG) | 2005-03-31 | — | — | WO | disclosed |
| WO-2000069900-A9 | PROTECTION OF ENDOGENOUS THERAPEUTIC PEPTIDES FROM PEPTIDASE ACTIVITY THROUGH CONJUGATION TO BLOOD COMPONENTS | CONJUCHEM INC (CA) | 2002-07-04 | — | — | WO | disclosed |
| EP-1105409-A2 | PROTECTION OF ENDOGENOUS THERAPEUTIC PEPTIDES FROM PEPTIDASE ACTIVITY THROUGH CONJUGATION TO BLOOD COMPONENTS | Conjuchem, Inc. (CA) | 2001-06-13 | — | — | EP | disclosed |
| WO-2000069900-A2 | PROTECTION OF ENDOGENOUS THERAPEUTIC PEPTIDES FROM PEPTIDASE ACTIVITY THROUGH CONJUGATION TO BLOOD COMPONENTS | CONJUCHEM, INC. (CA) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10201527-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | HDAC5, HDAC1, HDAC8 | KMT2A 96/4885HPGD 218/4885RAB9A 4449/4885 |
| US-20190282547-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | HDAC5, HDAC1, HDAC8 | KMT2A 96/4885HPGD 218/4885RAB9A 4449/4885 |
| US-20070043043-A1 | Benzimidazole derivates: preparation and pharmaceutical applications | HDAC5, HDAC1, HDAC4 | KMT2A 84/4885HPGD 218/4885RAB9A 4492/4885 |
| US-10736881-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | HDAC5, HDAC1, HDAC8 | KMT2A 96/4885HPGD 218/4885RAB9A 4449/4885 |
| US-20160279102-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | HDAC5, HDAC1, HDAC8 | KMT2A 96/4885HPGD 218/4885RAB9A 4449/4885 |
| US-20170360757-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | HDAC5, HDAC1, HDAC8 | KMT2A 96/4885HPGD 218/4885RAB9A 4449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.